We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Survival from breast cancer in women with a BRCA2 mutation by treatment.
- Authors
Evans, D. Gareth; Phillips, Kelly-Anne; Milne, Roger L.; Fruscio, Robert; Cybulski, Cezary; Gronwald, Jacek; Lubinski, Jan; Huzarski, Tomasz; Hyder, Zerin; Forde, Claire; Metcalfe, Kelly; Senter, Leigha; Weitzel, Jeffrey; Tung, Nadine; Zakalik, Dana; Ekholm, Maria; Sun, Ping; Narod, Steven A.; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group; Other members of the Polish Hereditary Breast Cancer Consortium
- Abstract
<bold>Background: </bold>The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation.<bold>Methods: </bold>We identified 664 women with stage I-III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features.<bold>Results: </bold>The 10-year breast-cancer survival for ER-positive patients was 78.9% and for ER-negative patients was 82.3% (adjusted HR = 1.23 (95% CI, 0.62-2.45, p = 0.55)). The 10-year breast-cancer survival for women who had a bilateral oophorectomy was 89.1% and for women who did not have an oophorectomy was 59.0% (adjusted HR = 0.45; 95% CI, 0.28-0.72, p = 0.001). The adjusted hazard ratio for chemotherapy was 0.83 (95% CI, 0.65-1.53: p = 0.56).<bold>Conclusions: </bold>For women with breast cancer and a germline BRCA2 mutation, positive ER status does not predict superior survival. Oophorectomy is associated with a reduced risk of death from breast cancer and should be considered in the treatment plan.
- Subjects
BREAST tumor treatment; PROTEIN metabolism; THERAPEUTIC use of antineoplastic agents; PROTEINS; SURVIVAL; RESEARCH; GENETIC mutation; RESEARCH methodology; RETROSPECTIVE studies; CELL receptors; PROGNOSIS; MEDICAL cooperation; EVALUATION research; COMPARATIVE studies; OVARIECTOMY; IMPACT of Event Scale; RESEARCH funding; MASTECTOMY; RADIOTHERAPY; COMBINED modality therapy; BREAST tumors; LONGITUDINAL method
- Publication
British Journal of Cancer, 2021, Vol 124, Issue 9, p1524
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/s41416-020-01164-1